Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.
Oxular, a UK-based retinal therapeutics developer backed by drug encapsulation company Hovione Scientia and contract pharmaceutical services provider Consort Medical, received $37m in funding yesterday. Venture capital firm Forbion Capital Partners led the round, which also featured investment firm NeoMed, commercialisation firm IP Group and V-Bio Ventures, a venture fund affiliated with life science institute…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.